metronidazole has been researched along with Long QT Syndrome in 9 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report documents the occurrence of torsades de pointes (TdP) caused by marked QT interval prolongation in the case of a 71-year-old woman receiving both metronidazole and amiodarone for the treatment of pseudomembranous colitis and paroxysmal atrial fibrillation." | 3.73 | QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. ( Efraimidis, M; Kardaras, F; Kounas, SP; Letsas, KP; Sideris, A, 2005) |
| " The most frequently reported treatment-emergent adverse events with SYM-1219 were headache, dizziness, and nausea." | 2.87 | Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals. ( Adetoro, N; Darpo, B; Matthews, BG; Pentikis, HS; Xue, H, 2018) |
| "To determine the most common drug-drug interaction (DDI) pairs contributing to QTc prolongation in cardiac intensive care units (ICUs)." | 1.39 | Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. ( Armahizer, MJ; Kane-Gill, SL; Seybert, AL; Smithburger, PL, 2013) |
| "Acquired long QT syndrome is a rare condition whose diagnosis is of vital importance given the risk of torsade de pointes and sudden death." | 1.36 | [Perioperative acquired long QT syndrome: a case report]. ( Arizaga, A; Goitia, L; Pérez, P; Sebastián, P; Taibo, JM, 2010) |
| "He had a 3." | 1.35 | Ciprofloxacin-induced Q-T interval prolongation. ( Knorr, JP; Moshfeghi, M; Sokoloski, MC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Darpo, B | 1 |
| Xue, H | 1 |
| Adetoro, N | 1 |
| Matthews, BG | 1 |
| Pentikis, HS | 1 |
| Goitia, L | 1 |
| Pérez, P | 1 |
| Sebastián, P | 1 |
| Taibo, JM | 1 |
| Arizaga, A | 1 |
| Altın, C | 1 |
| Kanyılmaz, S | 1 |
| Baysal, S | 1 |
| Özin, B | 1 |
| Yelve, K | 1 |
| Phatak, S | 1 |
| Patil, MA | 1 |
| Pazare, AR | 1 |
| Armahizer, MJ | 1 |
| Seybert, AL | 1 |
| Smithburger, PL | 1 |
| Kane-Gill, SL | 1 |
| Preskorn, SH | 1 |
| Kounas, SP | 1 |
| Letsas, KP | 1 |
| Sideris, A | 1 |
| Efraimidis, M | 1 |
| Kardaras, F | 1 |
| Cohen, O | 1 |
| Saar, N | 1 |
| Swartzon, M | 1 |
| Kliuk-Ben-Bassat, O | 1 |
| Justo, D | 1 |
| Knorr, JP | 1 |
| Moshfeghi, M | 1 |
| Sokoloski, MC | 1 |
1 trial available for metronidazole and Long QT Syndrome
| Article | Year |
|---|---|
Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals.
Topics: Adult; Antiprotozoal Agents; Cross-Over Studies; Electrocardiography; Female; Heart Rate; Humans; Lo | 2018 |
8 other studies available for metronidazole and Long QT Syndrome
| Article | Year |
|---|---|
[Perioperative acquired long QT syndrome: a case report].
Topics: Adjuvants, Anesthesia; Adrenergic beta-Antagonists; Amoxicillin-Potassium Clavulanate Combination; A | 2010 |
QT interval prolongation due to metronidazole administration.
Topics: Aged; Anti-Infective Agents; Cross Infection; Drug Therapy, Combination; Electrocardiography; Female | 2011 |
Syncope in a patient being treated for hepatic and intestinal amoebiasis.
Topics: Amebicides; Antiprotozoal Agents; Chloroquine; Dysentery, Amebic; Furans; Humans; Hypokalemia; Liver | 2012 |
Drug-drug interactions contributing to QT prolongation in cardiac intensive care units.
Topics: Amiodarone; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Anti-Infective Agents; Antipsychotic Agents | 2013 |
Drug-drug interactions: proof of relevance (part I).
Topics: Anti-Bacterial Agents; Antifungal Agents; Antipsychotic Agents; Cyclophilins; Drug Interactions; Dru | 2005 |
QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Drug Interacti | 2005 |
First report of metronidazole-induced QT interval prolongation.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Anti-Infective Agents; Female; Humans; Long QT Syndrome; | 2008 |
Ciprofloxacin-induced Q-T interval prolongation.
Topics: Abscess; Acetamides; Adolescent; Anti-Infective Agents; Aztreonam; Bradycardia; Ciprofloxacin; Crohn | 2008 |